MindRank AI

MindRank is a biotechnology company developing AI-powered approaches to small-molecule drug discovery. Its platform, Molecule Pro™, combines machine learning, biology, and chemistry to help identify and advance novel medicines, with a focus on hard-to-drug molecular targets. The company offers proprietary drug development and collaborates with biopharma partners through design-as-a-service and co-development programs.

MindRank’s proprietary candidate MDR-001 is an oral small-molecule GLP-1 receptor agonist being developed for obesity and type 2 diabetes. The AI-designed drug received US IND approval 19 months after the program began and has entered Phase III clinical trials. MindRank has also delivered an allosteric inhibitor PCC, described as having best-in-class potential, to a publicly traded biotechnology company.

The company’s team includes more than 40 scientists with experience in biopharma, drug discovery, and AI innovation. Its work has appeared in journals including Nature Biomedical Engineering, Patterns, and Advanced Science, and it has received industry recognition, including a place on Forbes Asia’s 2023 “100 to Watch” list.